**Appendix 1: Patient cohorts considered at highest risk from COVID-19 and to be prioritised for treatment with nMABs.**

The following patient cohorts were determined by an independent advisory group commissioned by the Department of Health and Social Care (DHSC).



Continued next page



Continued next page

